Derrick Rossi

Dr. Rossi is a stem cell scientist and serial biotech entrepreneur. His accomplishments at the forefront of regenerative medicine and biotechnology, particularly the development of modified-mRNA reprogramming, have led to recognition by Time magazine as one of the 100 Most Influential People in the world (2011) and one of the top ten medical breakthroughs (2010). The first company Dr. Rossi founded, Moderna, rose to global prominence in 2020 when it developed a COVID-19 vaccine now deployed around the world. Currently, Dr. Rossi is CEO of Convelo Therapeutics, a company developing remyelination therapeutics for patients suffering from demyelination diseases such as multiple sclerosis. He is co-founder of Stelexis Therapeutics, targeting the stem cell origin of cancer; Magenta Therapeutics, focused on transforming transplantation medicine; and Intellia Therapeutics, developing CRISPR/Cas9-based therapeutics. Prior to founding Moderna, Dr. Rossi was an Associate Professor at Harvard Medical School and Harvard University and an investigator at Boston Children’s Hospital, where he led a team working on stem cell biology and regenerative medicine. Dr. Rossi earned his his PhD from the University of Helsinki and his MSc and BSc from the University of Toronto.